Erlotinib Terminated Phase 1 Trials for EGFR Mutated EGFR TKI Naive Metastatic NSCLC Treatment

IndicationsStatusPurposePhase
TerminatedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02206763Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)